| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 05/02/2025 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 27/01/2025 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 18/01/2025 | 03:12 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 15/01/2025 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 13/01/2025 | 13:30 | GlobeNewswire Inc. | New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 06/01/2025 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 23/12/2024 | 22:30 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 23/12/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 23/12/2024 | 13:00 | GlobeNewswire Inc. | Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 16/12/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 09/12/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 02/12/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 26/11/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 25/11/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 31/10/2024 | 09:00 | GlobeNewswire Inc. | Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024 | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 23/10/2024 | 14:03 | InvestorsHub NewsWire | ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 17/10/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 15/10/2024 | 14:21 | InvestorsHub NewsWire | ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 01/10/2024 | 13:00 | InvestorsHub NewsWire | ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 03/09/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 06/08/2024 | 23:21 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 06/08/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 01/08/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 30/07/2024 | 23:20 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 30/07/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 29/07/2024 | 23:21 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 28/07/2024 | 23:00 | GlobeNewswire Inc. | Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 20/06/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 22/05/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences Announces Expansion of Leadership Team | NASDAQ:AVXL | Anavex Life Sciences Corporation |
| 14/05/2024 | 13:30 | GlobeNewswire Inc. | Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ | NASDAQ:AVXL | Anavex Life Sciences Corporation |
